Key takeaways
- • Trial: STEP-TEENS (NCT04102189) — Phase 3a, 201 participants over 68 weeks.
- • Drug studied: Wegovy (Semaglutide) — FDA-approved branded product.
- • Primary endpoint: Percent change in BMI from baseline to week 68 in adolescents 12 to under 18 with obesity
- • Key result: Mean BMI change -16.1% on semaglutide 2.4mg vs +0.6% on placebo in adolescents
- • Published: New England Journal of Medicine, 2022.
Study design
STEP-TEENS was a phase 3a randomized controlled trial enrolling 201 participants over 68 weeks. The trial studied Wegovy (Semaglutide) for obesity / overweight and was published in New England Journal of Medicine in 2022.
Primary endpoint
Percent change in BMI from baseline to week 68 in adolescents 12 to under 18 with obesity
Key results
| Measure | Value |
|---|---|
| Headline result | Mean BMI change -16.1% on semaglutide 2.4mg vs +0.6% on placebo in adolescents |
| Mean weight loss (highest dose arm) | 16.1% |
| Participants | 201 |
| Duration | 68 weeks |
| Phase | Phase 3a |
Citation
STEP-TEENS. Published in New England Journal of Medicine, 2022.
GLP1Zoom did not conduct this trial. We summarize published primary literature. For verbatim methods and full results, consult the primary publication and the ClinicalTrials.gov registry record.
Related
- Wegovy drug page — pricing, FDA status, side effects, alternatives
- All semaglutide trials
- GLP-1 clinical trials database
Other Wegovy trials
- STEP-1 — Mean weight loss 14
- STEP-2 — Mean weight loss 9
- STEP-3 — Mean weight loss 16
- STEP-4 — Participants continuing semaglutide lost an additional 7
- STEP-5 — Mean weight loss 15
Other Semaglutide trials
- SUSTAIN-1 (Ozempic) — HbA1c reduction 1
- SUSTAIN-6 (Ozempic) — 26% relative risk reduction in MACE on semaglutide vs placebo (HR 0
Important: This trial was conducted on the FDA-approved branded product Wegovy. Compounded versions of Semaglutide have NOT been studied in equivalent randomized controlled trials, and their efficacy and safety profile may differ.
GLP1Zoom is an affiliate-only comparator. We cite published trials; we do not conduct them. This page is informational and is not a substitute for personalized medical advice — always confirm any treatment decision with your prescribing clinician. Full disclaimer.